Cetera Investment Advisers Invitae Corp Transaction History

Cetera Investment Advisers

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.42 - $0.72 $1,482 - $2,541	3,530 Added 28.53%	15,901 $10,000
Q3 2023 Nov 14, 2023	BUY	$0.6 - $1.53 $793 - $2,024	1,323 Added 11.98%	12,371 $7,000
Q2 2023 Aug 09, 2023	SELL	$1.05 - $1.63 $5,344 - $8,296	-5,090 Reduced 31.54%	11,048 $12,000
Q1 2023 May 15, 2023	BUY	$1.2 - $2.73 $4,216 - $9,593	3,514 Added 27.84%	16,138 $21,000
Q4 2022 Feb 14, 2023	BUY	$1.71 - $3.61 $21,587 - $45,572	12,624 New	12,624 $23,000
Q2 2022 Aug 11, 2022	SELL	$2.13 - $9.01 $21,902 - $92,649	-10,283 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$6.28 - $15.59 $64,577 - $160,311	10,283 New	10,283 $82,000
Q4 2021 Feb 14, 2022	SELL	$14.7 - $28.67 $155,584 - $303,443	-10,584 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$24.31 - $33.6 $56,083 - $77,515	2,307 Added 27.87%	10,584 $301,000
Q2 2021 Aug 13, 2021	BUY	$26.09 - $40.4 $215,946 - $334,390	8,277 New	8,277 $279,000
Q1 2021 May 17, 2021	SELL	$33.06 - $56.93 $201,434 - $346,874	-6,093 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$39.09 - $57.4 $238,175 - $349,738	6,093 New	6,093 $255,000

2.12M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

Stay updated on Cetera Investment Advisers with notifications on news.